Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1971 1
1991 1
1993 1
1994 1
1995 1
1997 1
1998 2
1999 2
2000 2
2003 3
2006 4
2007 11
2008 9
2009 2
2010 2
2011 4
2012 1
2013 2
2014 4
2015 1
2016 2
2018 5
2019 1
2020 2
2021 3
2022 8
2023 10
2024 1

Text availability

Article attribute

Article type

Publication date

Search Results

76 results

Results by year

Filters applied: . Clear all
Page 1
Safety and efficacy of combination therapy with semaglutide, cilofexor and firsocostat in patients with non-alcoholic steatohepatitis: A randomised, open-label phase II trial.
Alkhouri N, Herring R, Kabler H, Kayali Z, Hassanein T, Kohli A, Huss RS, Zhu Y, Billin AN, Damgaard LH, Buchholtz K, Kjær MS, Balendran C, Myers RP, Loomba R, Noureddin M. Alkhouri N, et al. Among authors: billin an. J Hepatol. 2022 Sep;77(3):607-618. doi: 10.1016/j.jhep.2022.04.003. Epub 2022 Apr 16. J Hepatol. 2022. PMID: 35439567 Free article. Clinical Trial.
Metabolic reprogramming of the intestinal microbiome with functional bile acid changes underlie the development of NAFLD.
Smirnova E, Muthiah MD, Narayan N, Siddiqui MS, Puri P, Luketic VA, Contos MJ, Idowu M, Chuang JC, Billin AN, Huss RS, Myers RP, Boyett S, Seneshaw M, Min HK, Mirshahi F, Sanyal AJ. Smirnova E, et al. Among authors: billin an. Hepatology. 2022 Dec;76(6):1811-1824. doi: 10.1002/hep.32568. Epub 2022 Jun 23. Hepatology. 2022. PMID: 35561146 Free PMC article.
Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis.
Mózes FE, Lee JA, Vali Y, Alzoubi O, Staufer K, Trauner M, Paternostro R, Stauber RE, Holleboom AG, van Dijk AM, Mak AL, Boursier J, de Saint Loup M, Shima T, Bugianesi E, Gaia S, Armandi A, Shalimar, Lupșor-Platon M, Wong VW, Li G, Wong GL, Cobbold J, Karlas T, Wiegand J, Sebastiani G, Tsochatzis E, Liguori A, Yoneda M, Nakajima A, Hagström H, Akbari C, Hirooka M, Chan WK, Mahadeva S, Rajaram R, Zheng MH, George J, Eslam M, Petta S, Pennisi G, Viganò M, Ridolfo S, Aithal GP, Palaniyappan N, Lee DH, Ekstedt M, Nasr P, Cassinotto C, de Lédinghen V, Berzigotti A, Mendoza YP, Noureddin M, Truong E, Fournier-Poizat C, Geier A, Martic M, Tuthill T, Anstee QM, Harrison SA, Bossuyt PM, Pavlides M; LITMUS investigators. Mózes FE, et al. Lancet Gastroenterol Hepatol. 2023 Aug;8(8):704-713. doi: 10.1016/S2468-1253(23)00141-3. Epub 2023 Jun 5. Lancet Gastroenterol Hepatol. 2023. PMID: 37290471 Free article.
Machine learning algorithm improves the detection of NASH (NAS-based) and at-risk NASH: A development and validation study.
Lee J, Westphal M, Vali Y, Boursier J, Petta S, Ostroff R, Alexander L, Chen Y, Fournier C, Geier A, Francque S, Wonders K, Tiniakos D, Bedossa P, Allison M, Papatheodoridis G, Cortez-Pinto H, Pais R, Dufour JF, Leeming DJ, Harrison S, Cobbold J, Holleboom AG, Yki-Järvinen H, Crespo J, Ekstedt M, Aithal GP, Bugianesi E, Romero-Gomez M, Torstenson R, Karsdal M, Yunis C, Schattenberg JM, Schuppan D, Ratziu V, Brass C, Duffin K, Zwinderman K, Pavlides M, Anstee QM, Bossuyt PM; LITMUS investigators. Lee J, et al. Hepatology. 2023 Jul 1;78(1):258-271. doi: 10.1097/HEP.0000000000000364. Epub 2023 Mar 31. Hepatology. 2023. PMID: 36994719
A Fibrosis-Independent Hepatic Transcriptomic Signature Identifies Drivers of Disease Progression in Primary Sclerosing Cholangitis.
Gindin Y, Chung C, Jiang Z, Zhou JZ, Xu J, Billin AN, Myers RP, Goodman Z, Landi A, Houghton M, Green RM, Levy C, Kowdley KV, Bowlus CL, Muir AJ, Trauner M. Gindin Y, et al. Among authors: billin an. Hepatology. 2021 Mar;73(3):1105-1116. doi: 10.1002/hep.31488. Epub 2021 Feb 28. Hepatology. 2021. PMID: 32745270 Free PMC article.
Safety and Sustained Efficacy of the Farnesoid X Receptor (FXR) Agonist Cilofexor Over a 96-Week Open-label Extension in Patients With PSC.
Trauner M, Bowlus CL, Gulamhusein A, Hameed B, Caldwell SH, Shiffman ML, Landis C, Muir AJ, Billin A, Xu J, Liu X, Lu X, Chung C, Myers RP, Kowdley KV. Trauner M, et al. Among authors: billin a. Clin Gastroenterol Hepatol. 2023 Jun;21(6):1552-1560.e2. doi: 10.1016/j.cgh.2022.07.024. Epub 2022 Aug 4. Clin Gastroenterol Hepatol. 2023. PMID: 35934287 Clinical Trial.
NAFLD and NASH biomarker qualification in the LITMUS consortium - Lessons learned.
Rasmussen DGK, Anstee QM, Torstenson R, Golding B, Patterson SD, Brass C, Thakker P, Harrison S, Billin AN, Schuppan D, Dufour JF, Andersson A, Wigley I, Shumbayawonda E, Dennis A, Schoelch C, Ratziu V, Yunis C, Bossuyt P, Karsdal MA. Rasmussen DGK, et al. Among authors: billin an. J Hepatol. 2023 Apr;78(4):852-865. doi: 10.1016/j.jhep.2022.11.028. Epub 2022 Dec 14. J Hepatol. 2023. PMID: 36526000 Free article. Review.
Cilofexor, a Nonsteroidal FXR Agonist, in Patients With Noncirrhotic NASH: A Phase 2 Randomized Controlled Trial.
Patel K, Harrison SA, Elkhashab M, Trotter JF, Herring R, Rojter SE, Kayali Z, Wong VW, Greenbloom S, Jayakumar S, Shiffman ML, Freilich B, Lawitz EJ, Gane EJ, Harting E, Xu J, Billin AN, Chung C, Djedjos CS, Subramanian GM, Myers RP, Middleton MS, Rinella M, Noureddin M. Patel K, et al. Among authors: billin an. Hepatology. 2020 Jul;72(1):58-71. doi: 10.1002/hep.31205. Hepatology. 2020. PMID: 32115759 Clinical Trial.
76 results